Drug
Sofosbuvir/Velpatasvir/Voxilaprevir
Sofosbuvir/Velpatasvir/Voxilaprevir is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Phase Distribution
Ph phase_4
2
67%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Other(1)
Detailed Status
Completed2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (33.3%)
Phase 42 (66.7%)
Trials by Status
unknown133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
unknownphase_4
Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis
NCT05467826
completedphase_2
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience
NCT02745535
completedphase_4
Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
NCT03619837
Clinical Trials (3)
Showing 3 of 3 trials
NCT05467826Phase 4
Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis
NCT02745535Phase 2
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience
NCT03619837Phase 4
Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3